Kezar Life Sciences, Inc.
NCM: KZRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Kezar Life Sciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KZR Z-Score →About Kezar Life Sciences, Inc.
Healthcare
Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Kezar Life Sciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -59.9%, which indicates that capital utilization is currently under pressure.
At a current price of $7.37, KZR currently trades near the top of its 52-week range (96%) (Range: $3.53 - $7.55).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$54.33M
Trailing P/E
--
Forward P/E
-2.76
Beta (5Y)
0.43
52W High
$7.55
52W Low
$3.53
Avg Volume
60K
Day High
Day Low